EUVIMEDEUVIMED entdecken
Fallbericht

Effect of lemborexant on pharmacokinetics of clozapine: A potential drug–drug interaction mediated by time‐dependent inhibition of CYP3A4

Kenya Watanabe, Shingen Misaka iD, Keiko Kanno-Nozaki, Takaaki Chiyoda, Yuhei Suzuki, Akiko Sato, Takahiro Suto, Junko Kuroda, Kenju Shimomura iD, Itaru Miura, Hirooki Yabe iD

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.15889 ↗

Kurz gefasst

Fallbericht in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Kenya Watanabe und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Fukushima Medical University Hospital, Fukushima, Japan. Hauptthemen laut MEDLINE: Clozapine, Antipsychotic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clozapine (CLZ) is extensively used for treatment‐resistant schizophrenia (TRS) with caution to avoid serious adverse events such as agranulocytosis and drug–drug interactions (DDIs). In the current report, we present a case of a 35‐year‐old male non‐smoking TRS patient whose steady‐state plasma trough concentrations ( C trough ) of CLZ and its active metabolite, N ‐desmethylclozapine (NDMC), were significantly increased after initiating oral administration of lemborexant (LEM), a dual orexin receptor antagonist, for the treatment of insomnia. The patient experienced oversedation with sleepiness and fatigue while maintaining high levels of C trough of CLZ. The increased concentrations of CLZ returned to normal ranges after the discontinuation of LEM dosing, implying a pharmacokinetic DDI between CLZ and LEM. To gain insight into possible mechanisms, we performed in vitro assays of CYP1A2‐ and CYP3A4‐mediated CLZ metabolism by measuring the formations of NDMC and clozapine N ‐oxide (CNO). In accordance with previous studies, the incubation of CLZ with each enzyme resulted in the production of both metabolites. LEM had only a weak inhibitory effect on CYP1A2‐ and CYP3A4‐mediated CLZ metabolism. However, the preincubation of LEM with CYP3A4 in the presence of NADPH showed a significant enhancement of inhibitory effects on CLZ metabolism with IC 50 values for the formations of CNO and NDMC of 2.8 μM and 4.1 μM, respectively, suggesting that LEM exerts as a potent time‐dependent inhibitor for CYP3A4. Taken together, the results of the current study indicate that co‐medication of CLZ with LEM may lead to increase in exposure to CLZ and risks of CLZ‐related adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClozapineAntipsychotic AgentsMaleHumansAdultCytochrome P-450 CYP1A2Cytochrome P-450 CYP3ADrug InteractionsPyridinesPyrimidines

Stichwörter der Autor:innen

CYP1A2CYP3A4DORAclozapinelemborexantsuvorexanttime-dependent inhibition

Substanzen

ClozapineCytochrome P-450 CYP1A2Cytochrome P-450 CYP3AAntipsychotic AgentslemborexantPyridinesPyrimidinesCYP3A4 protein, human

Autor:innen und Institutionen

  • Department of Pharmacy, Fukushima Medical University Hospital, Fukushima, Japan.
  • Department of Bioregulation and Pharmacological Medicine, School of Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Department of Neuropsychiatry, School of Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.

ORCID-Profile: Shingen Misaka, Kenju Shimomura, Hirooki Yabe

Zitieren

APA

Watanabe, K., Misaka, S., Kanno-Nozaki, K., Chiyoda, T., Suzuki, Y., Sato, A., Suto, T., Kuroda, J., Shimomura, K., Miura, I., & Yabe, H. (2024). Effect of lemborexant on pharmacokinetics of clozapine: A potential drug–drug interaction mediated by time‐dependent inhibition of CYP3A4. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15889

Vancouver

Watanabe K, Misaka S, Kanno-Nozaki K, Chiyoda T, Suzuki Y, Sato A, et al. Effect of lemborexant on pharmacokinetics of clozapine: A potential drug–drug interaction mediated by time‐dependent inhibition of CYP3A4. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.15889

BibTeX
@article{Watanabe2024,
  author = {Watanabe, Kenya and Misaka, Shingen and Kanno-Nozaki, Keiko and Chiyoda, Takaaki and Suzuki, Yuhei and Sato, Akiko and Suto, Takahiro and Kuroda, Junko and Shimomura, Kenju and Miura, Itaru and Yabe, Hirooki},
  title = {Effect of lemborexant on pharmacokinetics of clozapine: A potential drug–drug interaction mediated by time‐dependent inhibition of CYP3A4},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.15889}
}
Kostenlos starten →